Inhibrx (INBX)$101.32

Market Cap: 178.49 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Inhibrx (INBX).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-0.4x

EV/FCF, N/A FCF yield

Quality

-1752.2%

ROIC, -9986.5% FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 3.9x current ratio

Superinvestors

Top: Viking Global Investors (0.3%)

Strengths to research

Debt/equity looks manageable at 0.0x.

Watchouts

Free cash flow margin is negative at -9986.5%.

Annual data: 3 periods

Quarterly data: 12 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for INBX.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


INBX Target	Inhibrx	$178.5M	-11.2x	-0.4x	-1752.2%	N/A	-9986.5%	N/A	N/A	N/A
DMAC	DiaMedica Therapeutics Inc.	$171.4M	N/A	-5.4x	-58.4%	N/A	N/A	N/A	N/A	N/A
CGEN	Compugen Ltd	$128.1M	7.4x	1.2x	34.4%	105.2%	43.1%	87.3%	-2.8x	N/A
COYA	Coya Therapeutics Inc	$107.2M	-3.8x	-5.6x	-49.3%	N/A	-135.2%	N/A	N/A	N/A
CRBU	Caribou Biosciences Inc.	$79.9M	-1.3x	-0.6x	-121.2%	-2.0%	-1006.8%	N/A	N/A	N/A
GUTS	Fractyl Health Inc	$79.8M	-0.5x	0.0x	-1490.3%	N/A	N/A	N/A	N/A	N/A
DNA	Ginkgo Bioworks Holdings Inc.	$402.4M	-1.5x	-1.3x	-0.1%	17.3%	-105.0%	N/A	N/A	N/A
ORIC	ORIC Pharmaceuticals Inc.	$405.2M	-5.7x	-3.2x	-33.7%	N/A	N/A	N/A	N/A	N/A
PGEN	Precigen Inc.	$448.7M	-3.1x	-5.7x	-219.7%	-21.3%	-927.6%	N/A	N/A	N/A

Financial Charts

No financial data available for INBX (annual).

1 superinvestors own INBX

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
Viking Global Investors Viking Global Investors	1,437,705	$97M	0.27%	0.0%